Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
81.95
-7.49 (-8.37%)
At close: Feb 18, 2025, 4:00 PM
83.03
+1.08 (1.32%)
Pre-market: Feb 19, 2025, 6:23 AM EST
Tempus AI Revenue
Tempus AI had revenue of $180.93M in the quarter ending September 30, 2024, with 32.98% growth. This brings the company's revenue in the last twelve months to $640.44M, up 32.13% year-over-year. In the year 2023, Tempus AI had annual revenue of $531.82M with 65.85% growth.
Revenue (ttm)
$640.44M
Revenue Growth
+32.13%
P/S Ratio
12.03
Revenue / Employee
$328,095
Employees
1,952
Market Cap
12.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 531.82M | 211.15M | 65.85% |
Dec 31, 2022 | 320.67M | 62.82M | 24.36% |
Dec 31, 2021 | 257.85M | 69.85M | 37.15% |
Dec 31, 2020 | 188.00M | 125.95M | 202.95% |
Dec 31, 2019 | 62.06M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TEM News
- 13 hours ago - Ares Management Upsizes Tempus Debt Facilities to $560 Million - Business Wire
- 21 hours ago - Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector - Seeking Alpha
- 21 hours ago - Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference - Business Wire
- 5 days ago - Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma - Business Wire
- 7 days ago - Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24 - Business Wire
- 13 days ago - Tempus AI: In Vogue, But Better To Wait For Some Retracement - Seeking Alpha
- 15 days ago - Tempus AI stock price is not cheap: is it a good buy? - Invezz
- 15 days ago - Tempus Completes Acquisition of Ambry Genetics - Business Wire